poisar

Stocks · News reference

Merck Announces Strategy For Rapid, Broad And Sustainable Access To Its HIV-1 Prevention Pill Alimatravir In Low- And Middle-Income Countries

Jul 24, 2026, 10:49 AMBenzinga Newsdesk

Initial access plans as part of Merck’s broader strategy include establishing early generic licensing covering 129 LMICs; supporting targeted, regional manufacturing capabilities in Africa and Latin America; and

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

MRK
Source
benzinga
Observed
Jul 24, 2026, 10:49 AM
Checked
Jul 24, 2026, 10:49 AM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Aug 27, 2026, 4:11 PMNa

    SMMT Rises on Akeso's Win in Phase III Biliary Tract Cancer Study

    Summit Therapeutics' partner Akeso announced positive phase III HARMONi-GI1 study results showing ivonescimab plus chemotherapy achieved superior overall survival compared to AstraZeneca's Imfinzi plus chemotherapy in advanced biliary tract cancer patients. The drug also met key secondary endpoints for progression-free survival and objective response rate. These results strengthen ivonescimab's development case beyond its initial NSCLC focus into colorectal and genitourinary cancers.

    Read original at zacks-investment-research
    SMMTAZNMRK